share_log

Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

獵戶座公司:截至2025年5月31日獵戶座集團執行管理委員會的變動
GlobeNewswire ·  05/07 13:30

ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS
7 May 2024 at 08.30 EEST
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

獵戶座公司
證券交易所新聞稿 — 更換董事會/管理層/核數師
2024 年 5 月 7 日美國東部標準時間 08:30
獵戶座公司:截至2025年5月31日獵戶座集團執行管理委員會的變動

Olli Huotari, Senior Vice President responsible for Corporate Functions organization (including, i.a., Communications, Compliance, Corporate Responsibility, Intellectual Property Rights, Legal Affairs and Public Affairs) of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group has informed the company of his decision to leave Orion. Orion will start a recruiting process of the successor to Olli Huotari. In order to secure a proper transition of responsibilities to his successor, Orion and Huotari have agreed that Huotari will continue in his current positions at Orion (including the membership of the Executive Management Board of the Orion Group) until 31 May 2025, after which he will leave the company.

負責獵戶座集團公司職能組織(包括溝通、合規、企業責任、知識產權、法律事務和公共事務)的高級副總裁兼獵戶座公司董事會秘書奧利·霍塔裏和獵戶座集團執行管理委員會成員已通知公司,他決定離開獵戶座。獵戶座將開始招募奧利·霍塔裏繼任者。爲了確保將責任適當移交給繼任者,獵戶座和霍塔裏已同意,霍塔裏將繼續擔任其目前在獵戶座的職位(包括獵戶座集團執行管理委員會的成員),直至2025年5月31日,之後他將離開公司。

Olli Huotari has held group-level leadership positions at Orion since 2002.

自2002年以來,奧利·霍塔裏一直在獵戶座擔任集團級領導職務。

President and CEO Liisa Hurme says:

總裁兼首席執行官麗莎·赫爾姆說:

"I want to warmly thank Olli for his great work for Orion. It is of course a pity when such a proficient and experienced leader wants to leave. However, as much as we would like to keep him with the company, we must respect his decision. We are pleased that Olli has agreed to continue working at Orion for a sufficient period in order to ensure a smooth transition of responsibilities and introduction of his successor. This also reflects Olli as a person − he always wants to make sure that the company's interests are taken care of."

“我要衷心感謝奧利爲獵戶座所做的出色工作。當這樣一位熟練和經驗豐富的領導者想要離開時,這當然是很可惜的。但是,儘管我們想讓他留在公司,但我們必須尊重他的決定。我們很高興奧利同意繼續在獵戶座工作一段時間,以確保順利移交職責和引進繼任者。這也反映了奧利作爲一個人——他一直想確保公司的利益得到照顧。”

Olli Huotari says:
"I have always appreciated and been very grateful for all the positions and career Orion has offered to me. Orion is a great company with great people. Until the end of May 2025, I will continue working for the company and will do my best so that my successor will have the best possible start in the new position. After that, I will move to the next phase of my life."

奧利·霍塔裏說道:
“我一直對獵戶座爲我提供的所有職位和職業生涯表示讚賞和感激。Orion 是一家擁有優秀人才的優秀公司。在2025年5月底之前,我將繼續爲公司工作,並將盡我所能,使我的繼任者在新職位上有儘可能好的開端。之後,我將進入人生的下一個階段。”

Orion Corporation

獵戶座公司

Liisa Hurme
President and CEO
Terhi Ormio
Vice President, Communications
Liisa Hurme
總裁兼首席執行官
Terhi Ormio
傳播副總裁


Contact person:
Liisa Hurme
President and CEO
tel. +358 50 966 2874


聯繫人:
Liisa Hurme
總裁兼首席執行官
電話:+358 50 966 2874

Contact person for the media:
Terhi Ormio, Vice President, Communications
tel. +358 50 966 4646
terhi.ormio@orion.fi

媒體聯繫人:
Terhi Ormio,傳播副總裁
電話:+358 50 966 4646
terhi.ormio@orion.fi

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland

出版商:
獵戶座公司
通信
Orionintie 1A,FI-02200 埃斯波,芬蘭

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Orion 是一家全球運營的芬蘭製藥公司,是幸福的締造者。我們開發、製造和銷售人類和獸藥以及活性藥物成分。Orion 擁有廣泛的專有和仿製藥以及消費者健康產品組合。我們藥物研發的核心治療領域是腫瘤學和疼痛。Orion 開發的專有產品用於治療癌症、神經系統疾病和呼吸系統疾病等。獵戶座在2023年的淨銷售額爲11.9億歐元,截至年底,該公司擁有約3600名員工。獵戶座的A股和B股在赫爾辛基納斯達克上市。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論